Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’
Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically…
2 years ago
APO’s Newest Member Turkiye Hosts 64th Workshop Meeting of Heads of National Productivity Organizations
ANKARA, Turkiye--(BUSINESS WIRE)--#APO--Turkiye, the Asian Productivity Organization’s (APO’s) newest member, generously hosted the 64th Workshop…
2 years ago
MindHub Academy 與廣州VV ARTç¶ç¶è—術創作åˆä½œ
MindHub Academy 與廣州VV ARTç¶ç¶è—術創作åˆä½œï¼ŒæŽ¨å‡ºå¤šæ¨£è—術課程，啟發創æ„æ–°æ½®æµ é¦™æ¸¯ - Media OutReach - 2023å¹´10月23æ—¥ - 在這個充滿活力的城市，一個令人振奮的消æ¯å³å°‡åœ¨è—術界掀起巨浪。MindHub Academy 和⌈廣州VV ARTç¶ç¶è—術創作…
2 years ago
Covation Holdings Continues Expansion in Asia Pacific With New Regional Corporate Headquarters
HONG KONG--(BUSINESS WIRE)--Covation Holdings Limited, the global manufacturer of multiple wheeled goods brands, today announced…
2 years ago
Berkshire Hathaway Specialty Insurance Names Sami Jaghbir as Underwriting Manager in Queensland
BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed…
2 years ago
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus…
2 years ago
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
Encouraging overall response rate of 46% and disease control rate of 98% with a median…
2 years ago
Correcting and Replacing: Lighting the Way to the Future: Renowned Brands Unveil Breakthroughs in the World-Renowned Lighting Marketplace
Buyer Registration Link HONG KONG SAR - Media OutReach - 22 October 2023 - Organised…
2 years ago
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab showed a confirmed objective response rate of…
2 years ago
CHNT Group Showed at The 24th Conference on The Electric Power Supply Industry
XIAMEN, China--(BUSINESS WIRE)--On October 20th, the 24th Conference on The Electric Power Supply Industry kicked…
2 years ago